Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Corcept Therapeutics ( (CORT) ) is now available.
On July 31, 2025, Corcept Therapeutics announced its financial results for the second quarter of 2025, reporting a revenue increase to $194.4 million from $163.8 million in the same quarter of 2024. Despite a slight decrease in net income, the company highlighted significant clinical development milestones, including the publication of results from its CATALYST and ROSELLA studies and ongoing New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Corcept’s advancements in clinical trials and strategic stock repurchases indicate a robust growth trajectory and potential leadership in cortisol modulation therapies.
The most recent analyst rating on (CORT) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ overall stock score is driven by its strong financial performance and promising corporate events, including a significant FDA submission. However, the high P/E ratio and technical analysis indicating neutral momentum mitigate the score, alongside risks highlighted in the earnings call.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics Incorporated is a commercial-stage company based in Redwood City, California, specializing in the discovery and development of medications that modulate the effects of the hormone cortisol. The company focuses on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders, and has introduced Korlym, the first FDA-approved medication for endogenous hypercortisolism.
Average Trading Volume: 1,314,403
Technical Sentiment Signal: Buy
Current Market Cap: $7.23B
See more insights into CORT stock on TipRanks’ Stock Analysis page.